PER 0.00% 8.0¢ percheron therapeutics limited

Ann: US FDA Type C Meeting for ATL1102 in DMD, page-34

  1. 703 Posts.
    lightbulb Created with Sketch. 109
    Others can spin it negatively - that's their prerogative.

    To me it is simply great news.

    As others have already pointed out the FDA focus is on "When" not "If".

    Together ANP and the FDA will just review if non-clinical issues may affect the timing. So obviously it has been determined that there are no current/outstanding clinical issues preventing the final phase testing.

    They are saying to ANP ... "When can you get ready for your Phase 2B/3" .. it's that simple.

    GLTAH
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.0¢
Change
0.000(0.00%)
Mkt cap ! $72.12M
Open High Low Value Volume
8.1¢ 8.1¢ 7.9¢ $33.53K 416.4K

Buyers (Bids)

No. Vol. Price($)
2 92000 7.9¢
 

Sellers (Offers)

Price($) Vol. No.
8.0¢ 65186 3
View Market Depth
Last trade - 16.10pm 15/07/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.